Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) fell 2% in Tuesday's regular trading session after seeing strong gains on Monday. What Happened: Ocugen's stock fell more than 2% to $9.15 in Tuesday's trading on disappointing news related to Covaxin, the COVID-19 vaccine of Ocugen's partner, India-based Bharat Biotech.

Ocugen Reverses Course From Monday's Massive Surge As COVID-19 Vaccine Partner Faces WHO Setback

DraftKings

General Electric

Lockheed Martin

General Electric, DraftKings, Lockheed Martin and Ocugen were our top stock trades for Wednesday. Now, here's how the charts are setting up.

4 Top Stock Trades for Wednesday: DKNG, GE, LMT, OCGN

OCGN stock is capping off a day full of gains with a finish in the red. Late afternoon misfortune caused the stock to tank in value.

OCGN Stock Plunges After WHO Delays Decision on COVAXIN Vaccine

Ocugen Inc. (NASDAQ: OCGN) shares are trading higher Tuesday ahead of a key World Health Organization meeting. The WHO meeting will decide whether or not to grant emergency use approval for the COVID-19 vaccine of Ocugens partner, India-based Bharat Biotech.

Ocugen Rallies Ahead Of WHO Meeting: What's Next?

OCGN stock is racing higher as the WHO kicks off its review of partner Bharat Biotech's COVAXIN vaccine. Here's what to know.

OCGN Stock Soars 30% as WHO Kicks Off COVAXIN Review

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 24% pre-market today. This is why it happened.

OCGN Stock: Why The Price Increased Today

Shares of Ocugen Inc. (NASDAQ: OCGN) surged almost 12.3% in Monday's regular trading session and another 38.5% in the after-hours session in anticipation of a key event taking place Tuesday. What Happened: Ocugen's shares saw notable gains on Monday ahead of a key meeting on Tuesday of the World Health Organization's (WHO) technical advisory group on whether to grant emergency use approval for the COVID-19 vaccine of Ocugen's partner, India-based Bharat Biotech.

Ocugen Stock Strikes Massive Gains Day Ahead Of Key Date: What You Should Know

Investors are in a speculative frenzy around COVAXIN ahead of a WHO meeting tomorrow. OCGN stock is rallying as a result.

OCGN Stock Alert: What Is Going on With Red-Hot Ocugen Today?

Aurinia Pharmaceuticals

2 Biotech Stocks That Could Go Parabolic This Week

Moderna

Cassava Sciences Inc

3 Biotech Stocks That Are Ridiculously Overpriced

OCGN stock has suffered as a Covid-19 vaccine latecomer, but news that Covaxin won emergency approval in India sent shares soaring. The post Ocugen Surged on Its Covid Vaccine Emergency Approval in India appeared first on InvestorPlace.

Ocugen Surged on Its Covid Vaccine Emergency Approval in India

There is a lot of uncertainty surrounding this biotech's prospects.

Is Now a Good Time to Buy Ocugen?

MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its head of Research and Development, Arun Upadhyay, PhD, will present pre-clinical data demonstrating how the company's second modifier gene therapy candidate, OCU410, could potentially be an effective therapeutic for Dry Age-related Macular Degeneration (Dry AMD).

Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference

Highly volatile, with a tendency to make unwarranted moves higher, it's best to not go long (or short) OCGN stock. The post This Ocugen Stock Rally Makes Little Sense, But Watch Out Going Short appeared first on InvestorPlace.

This Ocugen Stock Rally Makes Little Sense, But Watch Out Going Short

Dynavax Technologies

These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.

Why Shares of Dynavax Technologies, Ocugen, and Valneva Are on the Move Today

The stock soared more than 22% this past week.

Is Ocugen Stock Heading for a Crash?

Novavax

These COVID-19 vaccine makers are sinking on nothing more than good old-fashioned uncertainty.

Why Shares of Moderna, Novavax, and Ocugen Are Falling Today

Ocugen has historically had a terrible track record. There's little reason to think its current vaccine effort will end any better for OCGN stock.

Ocugen Is a Strong Sell, Vaccine Unlikely to Find Commercial Success

Positive developments for COVID-19 vaccine Covaxin appear to have kicked off a short squeeze.

Why Ocugen Stock Is Skyrocketing This Week

Covid-19 vaccine play Ocugen is seeing impressive investor interest today, with OCGN stock seeing double-digit gains at the time of writing. The post OCGN Stock: One Big Reason Why Ocugen Is Climbing Today appeared first on InvestorPlace.

OCGN Stock: One Big Reason Why Ocugen Is Climbing Today

InvestorPlace's Louis Navellier believes all Ocugen needs is a catalyst. On Oct. 4, OCGN stock got two.

Ocugen Stock Needs a Catalyst for Growth That Probably Isn't Coming

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 18.5% in Tuesday's regular trading session, extending gains to a second straight day. What Happened: Ocugen's shares extended their rally on Tuesday after it was reported that an expert panel of India's drug regulator has recommended Bharat Biotech's COVID-19 vaccine, Covaxin, for children between the age of two and 18.

Is This Going To Be The Next Big Factor For Ocugen (OCGN) Stock?

Vaxart

Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnered with Bharat Biotech.

Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up

The shares of Ocugen Inc (NASDAQ:OCGN) are flying up the charts today, last seen 17% higher to trade at $9.

News for Ocugen, Inc. Stock (OCGN)